modality · intermediate · partly written
mRNA medicines and vaccines
An mRNA medicine is a message that cells read to make a protein for a short time; it needs a lipid carrier to enter cells.
Also called: messenger RNA therapeutics
This describes published medicine for readers who want to understand how it works and what happened. It is not medical advice and says nothing about what any person should take.
The short version
An mRNA vaccine is a temporary recipe for one protein carried in fat particles. Cells read it, make the antigen and the mRNA is then broken down. Comirnaty reached 95 percent efficacy (8 versus 162 cases); CVnCoV, 48.2 percent (83 versus 145). 12345
Reported, not yet replicated
How it differs from a small molecule more
The medicine is information, not a binder, so potency is measured in immune response and cases prevented rather than an IC50. The RNA is fragile and must be packaged in lipid nanoparticles, and the chemistry of the RNA, the dose and the antigen design all affect how much protein is made. 254
Reported, not yet replicated
Two cases more
Comirnaty used nucleoside-modified RNA at 30 micrograms and reached 95 percent efficacy. CVnCoV used chemically unmodified RNA at 12 micrograms, in a trial where 50 percent of sequenced cases were variants of concern, and reached 48.2 percent. The trials did not isolate which difference mattered. 14
Contested
Limits of this record deep
Only vaccine cases were opened. Protein-replacement uses and effect duration are not covered. 12345
Our inference
What it is
Intervenes at
Same as small molecule
Dose, safety and efficacy are still established in randomised trials; the endpoint here is disease prevented. 1
Our inference
Changes downstream
Delivery
Persistence
The mRNA is broken down shortly after vaccination and cells temporarily make the protein; the duration of the immune response was not read. 2
Reported, not yet replicated
Examples
Teach this
In one sentence
An mRNA medicine is a short-lived message in a lipid particle that makes cells produce a protein, and in vaccines that protein trains the immune system. 12345
Reported, not yet replicated
The five-minute version
The medicine is the mRNA recipe plus a lipid carrier. After injection into muscle, cells read it and make the antigen briefly, and EMA says the mRNA is broken down shortly afterwards. Two vaccines using the platform diverged sharply in efficacy, 95 versus 48.2 percent, with differences in dose, RNA modification and variants that the trials cannot separate. 12345
Reported, not yet replicated
What a listener will ask
Why a lipid particle?
It protects the mRNA from breaking down too quickly (EMA).
Does it last?
EMA says the mRNA is broken down shortly after vaccination.
Why did CVnCoV do worse?
Not isolated; see the CVnCoV record.
The common wrong idea
mRNA medicines permanently change the cell.
The mRNA is temporary: cells temporarily make the protein and the mRNA is broken down shortly after vaccination (EMA).
The one citation to hand over: 3
Still open here
- Only vaccine cases were researched; mRNA therapeutics for protein replacement were not.
- How long the encoded protein persists was not measured in the sources opened.
Linked from
Sources
- Polack FP, Thomas SJ, Kitchin N, et al.. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 383:2603-2615 (2020). paper; opened 2026-11-17 all records citing this
- European Medicines Agency. EMA recommends first COVID-19 vaccine for authorisation in the EU. EMA news page (2020). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
- European Medicines Agency. Comirnaty: European public assessment report overview. EMA EPAR page (2026). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
- Kremsner PG, Ahuad Guerrero RA, Arana-Arri E, et al.. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial. Lancet Infect Dis 22:329-340 (2022). paper; opened 2026-11-17 all records citing this
- Morais P, Adachi H, Yu YT. The Critical Contribution of Pseudouridine to mRNA COVID-19 Vaccines. Front Cell Dev Biol 9:789427 (2021). review; opened 2026-11-17 all records citing this
History of this record (5)
This record has been changed 5 times, on the dates below. The note kept against each change is written for the people who maintain the atlas, in their own shorthand, so it is not shown here; it is in the record itself.
- Status
- partly written
- Last updated
- 2026-11-19
- Record
- content/modalities/mrna.json